3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
2
Fallopian Tube Neoplasms
2
Vulvar Neoplasms
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms
1
Gallbladder Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Neuroendocrine
1
Breast Neoplasms
1
Bile Duct Neoplasms
1
Interventions
Carboplatin
19
Paclitaxel
17
Cisplatin
9
Cyclophosphamide
8
Gemcitabine
7
Bevacizumab
6
Topotecan
5
pembrolizumab
4
olaparib
4
liposomal doxorubicin
4
durvalumab
4
Letrozole
4
Interleukin-2
4
Drug Therapy
4
Doxorubicin
4
Albumin-Bound Paclitaxel
4
rucaparib
3
fludarabine
3
chiauranib
3
cemiplimab
3
camrelizumab
3
Therapeutics
3
Itraconazole
3
Injections
3
Hyperthermic Intraperitoneal Chemotherapy
3
Everolimus
3
pazopanib
2
iniparib
2
eprenetapopt
2
avelumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
tivozanib
×
Gynecologic
×
Clear all
NCT01853644
2021-10-12
TIVO
Northwestern University
Phase 2
Completed
31 enrolled
12 charts